You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Link Details
- Metabolite
- HMDB0000122 (D-Glucose)
- DrugBank ID
- DB00412
- Drug Name
- Rosiglitazone
- Effect
- Decrease
- Biospecimen
- Blood
- P-value
- Not Available
- Beta Estimator
- Not Available
- Percent Change
- Not Available
- Pearson Correlation Coefficient
- Not Available
- Comments
- Not Available
- Wei J, Tang Q, Liu L, Bin J: Combination of peroxisome proliferator-activated receptor alpha/gamma agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion. Exp Ther Med. 2013 Mar;5(3):783-788. Epub 2013 Jan 10. [PubMed:23408783 ]
- Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ: The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med. 2012 Feb;125(2):126-33. doi: 10.1016/j.amjmed.2011.08.025. [PubMed:22269613 ]
- Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001 Jan;86(1):280-8. [PubMed:11232013 ]